MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.

Oncotarget · 2016 · PMC5342744 · PMID 27659536

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

did not reach statistical significanceP = 0.061so close (0.05 < p ≤ 0.1)

RG7112 significantly suppressed the growth of xenografted RMG-I cells ( P = 0.033 by t-test, Figure 4A-4C ) and tended to suppress the growth of the OVISE cells, although the growth suppression in OVISE cells did not reach statistical significance ( P = 0.061, Supplementary Figure 6A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.